258 related articles for article (PubMed ID: 20884431)
1. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
[TBL] [Abstract][Full Text] [Related]
2. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
3. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
[TBL] [Abstract][Full Text] [Related]
4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
5. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
[TBL] [Abstract][Full Text] [Related]
8. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.
Dudek D; Onuma Y; Ormiston JA; Thuesen L; Miquel-Hebert K; Serruys PW
EuroIntervention; 2012 Jan; 7(9):1060-1. PubMed ID: 21959320
[TBL] [Abstract][Full Text] [Related]
9. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
[TBL] [Abstract][Full Text] [Related]
11. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
[TBL] [Abstract][Full Text] [Related]
12. Bioabsorbable drug-eluting stents: the future of coronary angioplasty?
Macaya C; Moreno R
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):598-9. PubMed ID: 18679382
[TBL] [Abstract][Full Text] [Related]
13. Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment.
García-García HM; Schultz C; Duckers E; Regar E; Ligthart J; Serruys PW; van Geuns RJ
EuroIntervention; 2013 Feb; 8(10):1126-7. PubMed ID: 23014900
[No Abstract] [Full Text] [Related]
14. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Baldus S; Hauptmann KE; Suttorp MJ; Drzewiecki J; Pieper M; Schultheiss HP; Mauri L
EuroIntervention; 2010 Nov; 6(5):562-7. PubMed ID: 21044908
[TBL] [Abstract][Full Text] [Related]
15. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial.
Okamura T; Garg S; Gutiérrez-Chico JL; Shin ES; Onuma Y; García-García HM; Rapoza RJ; Sudhir K; Regar E; Serruys PW
EuroIntervention; 2010 Apr; 5(8):932-8. PubMed ID: 20542778
[TBL] [Abstract][Full Text] [Related]
17. Current status of the Xience V® everolimus-eluting coronary stent system.
Claessen BE; Caixeta A; Henriques JP; Piek JJ
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-eluting bioabsorbable stent--Abbot Vascular programme.
Onuma Y; Piazza N; Ormiston JA; Serruys PW
EuroIntervention; 2009 Dec; 5 Suppl F():F98-F102. PubMed ID: 22100687
[No Abstract] [Full Text] [Related]
19. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
20. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
Brugaletta S; Heo JH; Garcia-Garcia HM; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Smits PC; Koolen J; McClean D; Dorange C; Veldhof S; Rapoza R; Onuma Y; Bruining N; Ormiston JA; Serruys PW
Eur Heart J; 2012 Jun; 33(11):1325-33. PubMed ID: 22507972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
